Furthermore, non-functional SIRPα variant soluble proteins in preclinical models and anti-CD47 mAb in non-Hodgkin’s lymphoma patients have been combined with rituximab, resulting in tumor regression [241,242]. The gene discussed is SIRPA; the disease is neoplasm.